X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (416) 416
Paper (127) 127
Publication (99) 99
Report (29) 29
Newspaper Article (12) 12
Book / eBook (9) 9
Dissertation (5) 5
Book Review (3) 3
Data Set (3) 3
Conference Proceeding (2) 2
Web Resource (2) 2
Book Chapter (1) 1
Patent (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
experiment (141) 141
high energy physics - experiment (127) 127
particle physics (127) 127
physics (123) 123
physics - high energy physics - experiment (121) 121
hep (114) 114
humans (109) 109
cern lhc coll (95) 95
high energy physics (94) 94
index medicus (88) 88
experimental results (85) 85
oncology (82) 82
p p: scattering (79) 79
male (76) 76
13000 gev-cms (75) 75
female (75) 75
p p: colliding beams (74) 74
ex (67) 67
phenomenology (65) 65
middle aged (57) 57
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (54) 54
aged (54) 54
lung neoplasms - drug therapy (53) 53
adult (51) 51
carcinoma, non-small-cell lung - drug therapy (46) 46
subatomic physics (43) 43
subatomär fysik (43) 43
nuclear experiment (42) 42
chemotherapy (39) 39
lung neoplasms - pathology (39) 39
antineoplastic combined chemotherapy protocols - therapeutic use (35) 35
aged, 80 and over (32) 32
physics of elementary particles and fields (32) 32
treatment outcome (32) 32
background (31) 31
natural sciences (27) 27
naturvetenskap (27) 27
fysik (26) 26
physical sciences (26) 26
carcinoma, non-small-cell lung - pathology (25) 25
hematology, oncology and palliative medicine (25) 25
cancer (24) 24
erlotinib (23) 23
hep-ex (22) 22
gefitinib (21) 21
lung cancer, non-small cell (21) 21
lung neoplasms - mortality (21) 21
mass dependence (21) 21
particle physics - experiment (21) 21
channel cross section: branching ratio: upper limit (20) 20
hadron-hadron scattering (20) 20
survival (20) 20
animals (19) 19
astrophysics (19) 19
lung cancer (19) 19
quality of life (19) 19
antineoplastic agents - therapeutic use (18) 18
atlas (18) 18
carcinoma, non-small-cell lung - mortality (18) 18
care and treatment (18) 18
respiratory system (18) 18
bottom: particle identification (17) 17
mutation (17) 17
afatinib (16) 16
analysis (16) 16
channel cross section: upper limit (16) 16
neoplasm staging (16) 16
nsclc (16) 16
survival analysis (16) 16
therapy (16) 16
diphosphonates - therapeutic use (15) 15
double-blind method (15) 15
hematology (15) 15
mass spectrum: (15) 15
nuclear and particle physics. atomic energy. radioactivity (15) 15
open-label (15) 15
pulmonary/respiratory (15) 15
solid tumors (15) 15
z0: leptonic decay (15) 15
adolescent (14) 14
deoxycytidine - analogs & derivatives (14) 14
high energy astrophysical phenomena (14) 14
physics, particles & fields (14) 14
quinazolines - therapeutic use (14) 14
research (14) 14
resonance: production (14) 14
scattering [p p] (14) 14
survival rate (14) 14
top: pair production (14) 14
物理学 (14) 14
[ phys.hexp ] physics [physics]/high energy physics - experiment [hep-ex] (13) 13
bone metastases (13) 13
deoxycytidine - administration & dosage (13) 13
drug therapy (13) 13
final state:jet lepton (13) 13
jet: bottom (13) 13
metastasis (13) 13
peripheral vascular disease (13) 13
adenocarcinoma (12) 12
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (4) 4
Gerstein Science - Stacks (3) 3
Online Resources - Online (3) 3
Royal Ontario Museum - Stacks (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 141 - 151
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 577 - 589
Journal Article
Future Oncology, ISSN 1479-6694, 07/2011, Volume 7, Issue 7, pp. 817 - 825
Afatinib (BIBW 2992), a novel aniline-quinazoline derivative, irreversibly and equipotently targets the intrinsic kinase activity of all active ErbB receptor... 
afatinib | BIBW 2992 | EGFR/HER2 | TKI | NSCLC | GEFITINIB | TYROSINE KINASE | FAILURE | EGFR | TRIAL | THERAPY | ONCOLOGY | EGFR/HER2 INHIBITOR | HER2 | IRREVERSIBLE INHIBITOR
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 5, pp. 528 - 538
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S34 - S35
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9652, pp. 1809 - 1818
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2013, Volume 31, Issue 27, pp. 3327 - 3334
Journal Article
Therapeutic Advances in Medical Oncology, ISSN 1758-8359, 01/2018, Volume 10, p. 175883401775333
Journal Article
Therapeutic Advances in Medical Oncology, 01/2018, Volume 10
Four epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib, gefitinib, afatinib and osimertinib, are currently available for the... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase
Journal Article